Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ELAN's Cash-to-Debt is ranked higher than
100% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. ELAN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ELAN' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.88
ELAN's Equity-to-Asset is ranked higher than
100% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ELAN: 0.88 )
Ranked among companies with meaningful Equity-to-Asset only.
ELAN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.87  Med: 0.88 Max: 0.88
Current: 0.88
0.87
0.88
Interest Coverage No Debt
ELAN's Interest Coverage is ranked higher than
100% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. ELAN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ELAN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Altman Z-Score: 6.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % 5.47
ELAN's Operating Margin % is ranked higher than
100% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. ELAN: 5.47 )
Ranked among companies with meaningful Operating Margin % only.
ELAN' s Operating Margin % Range Over the Past 10 Years
Min: 0.19  Med: 4.93 Max: 9.72
Current: 5.47
0.19
9.72
Net Margin % -5.83
ELAN's Net Margin % is ranked higher than
100% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. ELAN: -5.83 )
Ranked among companies with meaningful Net Margin % only.
ELAN' s Net Margin % Range Over the Past 10 Years
Min: -10.75  Med: -7.25 Max: -1.64
Current: -5.83
-10.75
-1.64
ROE % -5.51
ELAN's ROE % is ranked higher than
100% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. ELAN: -5.51 )
Ranked among companies with meaningful ROE % only.
ELAN' s ROE % Range Over the Past 10 Years
Min: -5.51  Med: -3.24 Max: -1.36
Current: -5.51
-5.51
-1.36
ROA % -2.95
ELAN's ROA % is ranked higher than
100% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. ELAN: -2.95 )
Ranked among companies with meaningful ROA % only.
ELAN' s ROA % Range Over the Past 10 Years
Min: -3.65  Med: -2.42 Max: -1.18
Current: -2.95
-3.65
-1.18
ROC (Joel Greenblatt) % 11.92
ELAN's ROC (Joel Greenblatt) % is ranked higher than
100% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. ELAN: 11.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ELAN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 7.46  Med: 19.77 Max: 32.08
Current: 11.92
7.46
32.08
GuruFocus has detected 1 Warning Sign with Elanco Animal Health Inc ELAN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ELAN's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NYSE:ELAN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Elanco Animal Health Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare: » details
Headquarter Location:


Top Ranked Articles about Elanco Animal Health Inc

Vanguard Health Care Fund Buys 4 Stocks in 3rd Quarter The fund’s largest new position is Elanco Animal Health
The Vanguard Health Care Fund (Trades, Portfolio) released its third-quarter portfolio last week, listing four new positions. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 33.78
ELAN's Forward PE Ratio is ranked higher than
100% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.60 vs. ELAN: 33.78 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.60
ELAN's PB Ratio is ranked higher than
100% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. ELAN: 1.60 )
Ranked among companies with meaningful PB Ratio only.
ELAN' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.65
Current: 1.6
0
1.65
PS Ratio 4.23
ELAN's PS Ratio is ranked higher than
100% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ELAN: 4.23 )
Ranked among companies with meaningful PS Ratio only.
ELAN' s PS Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.26
Current: 4.23
0
4.26
Price-to-Free-Cash-Flow 161.14
ELAN's Price-to-Free-Cash-Flow is ranked higher than
100% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.84 vs. ELAN: 161.14 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ELAN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0  Med: 0 Max: 163.52
Current: 161.14
0
163.52
Price-to-Operating-Cash-Flow 69.68
ELAN's Price-to-Operating-Cash-Flow is ranked higher than
100% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. ELAN: 69.68 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ELAN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0  Med: 0 Max: 70.7
Current: 69.68
0
70.7
EV-to-EBIT 74.87
ELAN's EV-to-EBIT is ranked higher than
100% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. ELAN: 74.87 )
Ranked among companies with meaningful EV-to-EBIT only.
ELAN' s EV-to-EBIT Range Over the Past 10 Years
Min: 0  Med: 0 Max: 75.99
Current: 74.87
0
75.99
EV-to-EBITDA 25.59
ELAN's EV-to-EBITDA is ranked higher than
100% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. ELAN: 25.59 )
Ranked among companies with meaningful EV-to-EBITDA only.
ELAN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0 Max: 25.97
Current: 25.59
0
25.97
EV-to-Revenue 4.13
ELAN's EV-to-Revenue is ranked higher than
100% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. ELAN: 4.13 )
Ranked among companies with meaningful EV-to-Revenue only.
ELAN' s EV-to-Revenue Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 4.13
Current Ratio 3.68
ELAN's Current Ratio is ranked higher than
100% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. ELAN: 3.68 )
Ranked among companies with meaningful Current Ratio only.
ELAN' s Current Ratio Range Over the Past 10 Years
Min: 3.15  Med: 3.36 Max: 3.68
Current: 3.68
3.15
3.68
Quick Ratio 1.88
ELAN's Quick Ratio is ranked higher than
100% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. ELAN: 1.88 )
Ranked among companies with meaningful Quick Ratio only.
ELAN' s Quick Ratio Range Over the Past 10 Years
Min: 1.68  Med: 1.73 Max: 1.88
Current: 1.88
1.68
1.88
Days Inventory 159.98
ELAN's Days Inventory is ranked higher than
100% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. ELAN: 159.98 )
Ranked among companies with meaningful Days Inventory only.
ELAN' s Days Inventory Range Over the Past 10 Years
Min: 113.41  Med: 175.08 Max: 236.74
Current: 159.98
113.41
236.74
Days Sales Outstanding 72.54
ELAN's Days Sales Outstanding is ranked higher than
100% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. ELAN: 72.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
ELAN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.69  Med: 72.49 Max: 73.29
Current: 72.54
71.69
73.29
Days Payable 45.00
ELAN's Days Payable is ranked higher than
100% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. ELAN: 45.00 )
Ranked among companies with meaningful Days Payable only.
ELAN' s Days Payable Range Over the Past 10 Years
Min: 45  Med: 54.45 Max: 59.11
Current: 45
45
59.11

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 11.37
ELAN's Price-to-Net-Current-Asset-Value is ranked higher than
100% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. ELAN: 11.37 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ELAN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 0 Max: 11.54
Current: 11.37
0
11.54
Price-to-Tangible-Book 5.71
ELAN's Price-to-Tangible-Book is ranked higher than
100% of the 749 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. ELAN: 5.71 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ELAN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0  Med: 0 Max: 5.8
Current: 5.71
0
5.8
Earnings Yield (Greenblatt) % 1.33
ELAN's Earnings Yield (Greenblatt) % is ranked higher than
100% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. ELAN: 1.33 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ELAN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.5
Current: 1.33
0
1.5

More Statistics

Revenue (TTM) (Mil) $2,957.80
EPS (TTM) $ -0.79
52-Week Range $30.10 - 37.61
Shares Outstanding (Mil)365.63

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 3,020 3,080 3,187 3,301
EBIT (Mil $) 505 562 661 713
EBITDA (Mil $) 607 663 760 828
EPS ($) 0.99 1.06 1.30 1.35
EPS without NRI ($) 0.99 1.06 1.30 1.35
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 0.25 0.26

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}